Gene therapy: trials and tribulations (original) (raw)

• Li, S. & Huang, L. Nonviral gene therapy: promises and challenges. Gene Ther. 7, 31– 34 (2000).
  Article CAS PubMed Google Scholar
• Templeton, N. S. & Lasic, D. D. (eds) Gene Therapy: Therapeutic Mechanisms and Strategies (Marcel Dekker, Inc., New York, 2000).This book has several excellent chapters on viral and non-viral vectors written by experts in the field. It also describes a number of therapeutic approaches to diseases and requirements for regulatory affairs.
  Google Scholar
• Friedmann, T. (ed.) The Development of Human Gene Therapy (Cold Spring Harbor Laboratory Press, New York, 1999).
  Google Scholar
• Verma, I. M. Gene therapy. Sci. Am. 263, 68– 72 (1990).
  Article CAS PubMed Google Scholar
• Anderson, W. F. Human gene therapy. Nature 392, 25– 30 (1998).
  Article CAS PubMed Google Scholar
• Mulligan, R. C. The basic science of gene therapy. Science 260, 926–932 (1993).
  Article CAS PubMed Google Scholar
• Miller, A. D. Human gene therapy comes of age. Nature 357, 455–460 (1992).
  Article CAS PubMed Google Scholar
• Markowitz, D., Goff, S. & Bank, A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62, 1120– 1124 (1988).
  CAS PubMed PubMed Central Google Scholar
• Danos, O. & Mulligan, R. C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl Acad. Sci. USA 85, 6460– 6464 (1988).
  Article CAS PubMed PubMed Central Google Scholar
• Burns, J. C., Friedmann, T., Driever, W., Burrascano, M. & Yee, J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and non-mammalian cells. Proc. Natl Acad. Sci. USA 90, 8033–8037 (1993).Use of vesicular stomatitis virus glycoprotein (VSVG) to replace the envelope protein in MLV vectors. The resulting chimeric virus, containing VSVG protein, is pantropic and can be concentrated by ultracentrifugation.
  Article CAS PubMed PubMed Central Google Scholar
• Yu, S. F. et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl Acad. Sci. USA 83, 3194–3198 (1986).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan, R. A. & Anderson, W. F. Human gene therapy. Annu. Rev. Biochem. 62, 191–217 (1993).
  Article CAS PubMed Google Scholar
• St Louis, D. & Verma, I. M. An alternative approach to somatic cell gene therapy. Proc. Natl Acad. Sci. USA 85, 3150–3154 (1988). On transplantation of retrovirally-transduced mouse fibroblasts, producing and secreting human factor IX protein, the transcription of the transgene is `shut off'.
  Article CAS PubMed PubMed Central Google Scholar
• Palmer, T. D., Rosman, G. J., Osborne, W. R. & Miller, A. D. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl Acad. Sci. USA 88, 1330–1334 ( 1991).
  Article CAS PubMed PubMed Central Google Scholar
• Lewis, P., Hensel, M. & Emerman, M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 11, 3053– 3058 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Bukrinsky, M. I. et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365, 666–669 (1993).
  Article CAS PubMed Google Scholar
• Frankel, A. D. & Young, J. A. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67, 1–25 (1998).
  Article CAS PubMed Google Scholar
• Naldini, L. et al. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 272, 263–267 (1996).The first use of a lentiviral vector to transduce genes in vitro and in vivo in non-dividing cells. The lentiviral vector was packaged in VSVG envelope protein to expand the host range.
  Article CAS PubMed Google Scholar
• Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H. & Verma, I. M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genet. 17, 314–317 ( 1997).
  Article CAS PubMed Google Scholar
• Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnol. 15 , 871–875 (1997).
  Article CAS Google Scholar
• Zennou, V. et al. HIV-1 genome nuclear import is mediated by a central DNA flap . Cell 101, 173–185 (2000).
  Article CAS PubMed Google Scholar
• Follenzi, A., Ailles, L. E., Bakovic, S., Geuna, M. & Naldini, L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences . Nature Genet. 25, 217– 222 (2000).
  Article CAS PubMed Google Scholar
• Zufferey, R., Donello, J. E., Trono, D. & Hope, T. J. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73, 2886–2892 ( 1999).
  CAS PubMed PubMed Central Google Scholar
• Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H. & Verma, I. M. Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150– 8157 (1998).
  CAS PubMed PubMed Central Google Scholar
• Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873–9880 (1998).
  CAS PubMed PubMed Central Google Scholar
• Johnston, J. C. et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73, 4991–5000 (1999).
  CAS PubMed PubMed Central Google Scholar
• Schnell, T., Foley, P., Wirth, M., Munch, J. & Uberla, K. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum. Gene Ther. 11, 439–447 ( 2000).
  Article CAS PubMed Google Scholar
• Poeschla, E. M., Wong-Staal, F. & Looney, D. J. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nature Med. 4, 354–357 ( 1998).
  Article CAS PubMed Google Scholar
• Mitrophanous, K. et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6, 1808– 1818 (1999).
  Article CAS PubMed Google Scholar
• Carter, P. J. & Samulski, R. J. Adeno-associated viral vectors as gene delivery vehicles. Int. J. Mol. Med. 6, 17–27 (2000).
  CAS PubMed Google Scholar
• Berns, K. I. in Fields Virology (eds Fields, B. N., Knipe, D. M. & Howley P. M.,) 2173–2198 (Lippincott–Raven, Philadelphia, 1996).
  Google Scholar
• Kotin, R. M. et al. Site-specific integration by adeno-associated virus. Proc. Natl Acad. Sci. USA 87, 2211– 2215 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Inoue, N., Hirata, R. K. & Russell, D. W. High-fidelity correction of mutations at multiple chromosomal positions by adeno-associated virus vectors. J. Virol. 73, 7376–7380 ( 1999).
  CAS PubMed PubMed Central Google Scholar
• Summerford, C. & Samulski, R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438– 1445 (1998).
  CAS PubMed PubMed Central Google Scholar
• Girod, A. et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nature Med. 5, 1052–1056 (1999).
  Article CAS PubMed Google Scholar
• Malik, P. et al. Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. J. Virol. 71, 1776– 1783 (1997).
  CAS PubMed PubMed Central Google Scholar
• Kay, M. A. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genet. 24, 257–261 ( 2000).Gives the first hints of successful gene therapy in haemophilia B patients by using recombinant adeno-associated viral vectors. Expression of transduced factor IX could be detected in one patient.
  Article CAS PubMed Google Scholar
• Yan, Z., Zhang, Y., Duan, D. & Engelhardt, J. F. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl Acad. Sci. USA 97, 6716– 6721 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Nakai, H., Storm, T. A. & Kay, M. A. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nature Biotechnol. 18, 527–532 (2000).
  Article CAS Google Scholar
• Shenk, T. in Fields Virology (eds Fields, B. N., Knipe D. M. & Howley, P. M.) 2111–2148 (Lippincott–Raven, Philadelphia, 1996).
  Google Scholar
• Yeh, P. & Perricaudet, M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J. 11, 615–623 (1997).
  Article CAS PubMed Google Scholar
• Kochanek, S. et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl Acad. Sci. USA 93, 5731–5736 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Parks, R. J. et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl Acad. Sci. USA 93, 13565– 13570 (1996).References 42 and 43 describe the generation of new adenoviral, `gutless', vectors in which all the viral genes required for viral propagation are provided in trans . The gutless vectors show long-term expression of the transgene.
  Article CAS PubMed PubMed Central Google Scholar
• Morral, N. et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl Acad. Sci. USA 96, 12816–12821 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Dai, Y. et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl Acad. Sci. USA 92, 1401–1405 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Kafri, T. et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl Acad. Sci. USA 95, 11377 –11382 (1998).Even physically inactivated adenoviral particles can generate a cytotoxic T-cell response, raising concerns about adenoviral vectors as suitable tools for long-term gene therapy.
  Article CAS PubMed PubMed Central Google Scholar
• Tripathy, S. K., Black, H. B., Goldwasser, E. & Leiden, J. M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545–550 ( 1996).
  Article CAS PubMed Google Scholar
• Wagner, R. R., & Rose, J. K. in Fields Virology (eds Fields, B. N., Knipe D. M. & Howley, P. M.) 1121– 1136 (Lippincott–Raven, Philadelphia, 1996).
  Google Scholar
• Chirmule, N. et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. 74, 2420–2425 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Halbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W. & Miller, A. D. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74, 1524–1532 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Fields, P. A. et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol. Ther. 1, 225–235 ( 2000).
  Article CAS PubMed Google Scholar
• Xiao, W. et al. Route of adminstration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol. Ther. 1, 323–329 ( 2000).
  Article CAS PubMed Google Scholar
• Wang, L., Takabe, K., Bidlingmaier, S. M., Ill, C. R. & Verma, I. M. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc. Natl Acad. Sci. USA 96, 3906–3910 ( 1999).
  Article CAS PubMed PubMed Central Google Scholar
• Scriver, C. R. S., Beaudet, A. L., Sly, W. S. & Valle, D. V. (eds) The Metabolic Basis of Inherited Disease (McGraw–Hill, New York, 1989).
  Google Scholar
• Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-XI disease. Science 288, 669– 672 (2000).The first definitive example of successful gene therapy, in three children suffering from SCID-XI. The haematopoietic stem cells from the patients were transduced by recombinant retroviruses expressing the γc–subunit, which is common to many interleukin receptors.
  Article CAS PubMed Google Scholar
• Kohn, D. B. et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nature Med. 4, 775–780 (1998).
  Article CAS PubMed Google Scholar
• Blaese, R. M. et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270, 475– 480 (1995).
  Article CAS PubMed Google Scholar
• Bordignon, C. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270, 470–475 (1995).
  Article CAS PubMed Google Scholar
• Miyoshi, H., Smith, K. A., Mosier, D. E., Verma, I. M. & Torbett, B. E. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283, 682– 686 (1999).
  Article CAS PubMed Google Scholar
• Guenechea, G. et al. Transduction of human CD34+CD38− bone marrow and cord-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol. Ther. 1, 566– 573 (2000).References 59 and 60 show successful long-term transduction of human haematopoietic stem cells by lentiviral vectors, without the use of agents such as growth factors and cytokines.
  Article CAS PubMed Google Scholar
• Snyder, R. O. et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genet. 16, 270–276 (1997).
  Article CAS PubMed Google Scholar
• Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A. & Verma, I. M. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol. Ther. 1, 154– 158 (2000).
  Article CAS PubMed Google Scholar
• May, C. et al. Therapeutic haemoglobin synthesis in thalassaemic mice expressing lentivirus-encoded human-globin. Nature 406, 82–86 (2000).
  Article CAS PubMed Google Scholar
• Cosset, F. L. & Russell, S. J. Targeting retrovirus entry. Gene Ther. 3, 946–956 ( 1996).
  CAS PubMed Google Scholar
• Wickham, T. J. Targeting adenovirus. Gene Ther. 7, 110– 114 (2000).
  Article CAS PubMed Google Scholar
• Boerger, A. L., Snitkovsky, S. & Young, J. A. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc. Natl Acad. Sci. USA 96, 9867–9872 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Bartlett, J. S., Kleinschmidt, J., Boucher, R. C. & Samulski, R. J. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'γ)2 antibody. Nature Biotechnol. 17, 181–186 ( 1999); erratum 17, 393 (1999).
  Article CAS Google Scholar
• Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 89, 5547–5551 (1992).First description of a regulable gene expression system that uses tetracycline. The transgene is `turned off' in the presence of tetracycline and `turned on' in its absence.
  Article CAS PubMed PubMed Central Google Scholar
• Urlinger, S. et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc. Natl Acad. Sci. USA 97, 7963– 7968 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Maxwell, I. H., Spitzer, A. L., Long, C. J. & Maxwell, F. Autonomous parvovirus transduction of a gene under control of tissue-specific or inducible promoters. Gene Ther. 3, 28 –36 (1996).
  CAS PubMed Google Scholar
• Kafri, T., Van Praag, H., Gage, F. H. & Verma, I. M. Lentiviral vectors: Regulated gene expression. Mol. Ther. 1, 516–521 (2000).
  Article CAS PubMed Google Scholar
• Wang, Y., O'Malley, B. W. Jr, Tsai, S. Y. & O'Malley, B. W. A regulatory system for use in gene transfer. Proc. Natl Acad. Sci. USA 91, 8180– 8184 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• No, D., Yao, T. P. & Evans, R. M. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl Acad. Sci. USA 93, 3346–3351 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Suhr, S. T., Gil, E. B., Senut, M. C. & Gage, F. H. High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc. Natl Acad. Sci. USA 95, 7999–8004 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Spencer, D. M., Wandless, T. J., Schreiber, S. L. & Crabtree, G. R. Controlling signal transduction with synthetic ligands. Science 262, 1019–1024 ( 1993).
  Article CAS PubMed Google Scholar
• Ye, X. et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283, 88–91 (1999).
  Article CAS PubMed Google Scholar
• Miyoshi, H., Takahashi, M., Gage, F. H. & Verma, I. M. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl Acad. Sci. USA 16, 10319 –10323 (1997).
  Article Google Scholar